Trial · NCT00746785

A New Pharmacotherapy for Alcohol Dependence: Olanzapine

NCT00746785, Phase 3, Completed, The Mind Research Network; results first posted 2014-03-20

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A New Pharmacotherapy for Alcohol Dependence: Olanzapine. Trials, record NCT00746785. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00746785

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A New Pharmacotherapy for Alcohol Dependence: Olanzapine
NCT number: NCT00746785
Status: Completed
Phases: Phase 3
Enrollment: 304 participants, actual
Lead sponsor: The Mind Research Network
Conditions: Alcohol Dependence
Interventions: 2.5 mg Olanzapine, 5mg Olanzapine, placebo
First posted: 2008-09-04
Last updated: 2014-03-20
Results first posted: 2014-03-20

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Drinks Per Drinking Day	up to 36 weeks	Drinks are measured as the number of standard alcoholic beverages consumed each day, assessed in varying lengths of time (i.e., 2 weeks, 4 weeks, 6 weeks, etc.). A standard alcoholic beverage is equivalent to: 1, 12 oz. regular beer; 1, 5 oz. glass of wine; 1, mixed drink with one1.5 oz shot; or 1, 1.5 oz shot. A drinking day is measured as any day of the week in which an alcoholic beverage is consumed. Data for drinks per drinking day is gathered using the "Time Line Follow Back" method in which participants are asked to recall their alcohol consumption day by day for a pre-defined set of time.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Drinks Per Drinking Day	up to 36 weeks		Drinks per drinking day	MEAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Drinks Per Drinking Day	A - 2.5 mg Olanzapine	8.7	Standard Deviation 5.3	Drinks per drinking day
Drinks Per Drinking Day	B - 5 mg Olanzapine	8.9	Standard Deviation 5.1	Drinks per drinking day
Drinks Per Drinking Day	C - Placebo	9.2	Standard Deviation 5.4	Drinks per drinking day

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	A - 2.5 mg Olanzapine	43
Overall Study	STARTED	B - 5 mg Olanzapine	46
Overall Study	STARTED	C - Placebo	40
Overall Study	COMPLETED	A - 2.5 mg Olanzapine	14
Overall Study	COMPLETED	B - 5 mg Olanzapine	21
Overall Study	COMPLETED	C - Placebo	13
Overall Study	NOT COMPLETED	A - 2.5 mg Olanzapine	29
Overall Study	NOT COMPLETED	B - 5 mg Olanzapine	25
Overall Study	NOT COMPLETED	C - Placebo	27

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diabetic Episode	General disorders	A - 2.5 mg Olanzapine	0	43	0
other	Diabetic Episode	General disorders	B - 5 mg Olanzapine	1	46	1
other	Diabetic Episode	General disorders	C - Placebo	0	40	0
other	Rectal Bleeding	Gastrointestinal disorders	A - 2.5 mg Olanzapine	1	43	1
other	Rectal Bleeding	Gastrointestinal disorders	B - 5 mg Olanzapine	0	46	0
other	Rectal Bleeding	Gastrointestinal disorders	C - Placebo	0	40	0
other	Orthostasis	General disorders	A - 2.5 mg Olanzapine	1	43	1
other	Orthostasis	General disorders	B - 5 mg Olanzapine	0	46	0
other	Orthostasis	General disorders	C - Placebo	0	40	0
other	Abdominal pain/palpable mass	General disorders	A - 2.5 mg Olanzapine	0	43	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	A - 2.5 mg Olanzapine
Total, all-cause mortality	B - 5 mg Olanzapine
Total, all-cause mortality	C - Placebo
Total, other adverse events	A - 2.5 mg Olanzapine	2	43
Total, other adverse events	B - 5 mg Olanzapine	2	46
Total, other adverse events	C - Placebo	0	40
Total, serious adverse events	A - 2.5 mg Olanzapine	0	43
Total, serious adverse events	B - 5 mg Olanzapine	0	46
Total, serious adverse events	C - Placebo	0	40

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01AA014886	A New Pharmacotherapy for Alcohol Dependence: Olanzapine	HUTCHISON, KENT E.	THE MIND RESEARCH NETWORK	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2006 to 2010

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00746785

GET https://conductscience.org/api/trials/v1/NCT00746785/registered

API reference For AI assistants